We stand with patients
Braeburn is committed to the fight against opioid use disorder.
Opioid addiction, also known as opioid use disorder (OUD), is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines are developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities.
Opioid overdose and misuse are a significant public health crisis in the U.S. today.1
1HHS.gov, Oct 2019, Opioid epidemic by Numbers, Accessed 02/27/2020 https://www.hhs.gov/opioids/about-the-epidemic/index.html
Next Generation Technology
FluidCrystal®* Injection Depot Technology, a next generation proprietary delivery system, includes a lipid-based liquid with a dissolved active ingredient. Upon injection and contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which encapsulates the active ingredient, allowing for a slow release of the medication over time.
*FluidCrystal® trademark is owned by Camurus and used by Braeburn under license.
Discover More
Patient Journey
Everything we think, say and do is with our patients in mind.
Innovation
We develop next generation therapies for opioid use disorder treatment.
Culture
We are proud to be part of the solution.
Our Talented Team
Braeburn strives to foster high performing teams that are passionate about being on the front lines of addressing the opioid crisis. We work smarter by leveraging technology and fostering a collaborative environment that encourages individuals to share their talents and voices to bring ideas to life.
Our Values
Integrity
Excellence
Respect
Accountability
Balance
